The U.S. Food and Drug Administration (FDA) Grants Accelerated Approval to Epcoritamab-Bysp (Epkinly) for Relapsed or Refractory Follicular Lymphoma
On June 26, 2024, the U.S. Food and Drug Administration (FDA) announced it has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines…